BDTX vs HUBCW Comparison

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Hub Cyber Security Ltd is engaged in developing reliable quality assurance systems that support process and product enhancement and also operates in the industry of secured data fabric. The company serves various organizations and institutions operating in the security, electronics, aviation, telecommunications, and banking. The company has two operating segments: Product and Technology Segment and Professional Services Segment. The majority of revenue comes from the professional services segment, which provides data and cybersecurity and system security and reliability solutions and related services such as consulting, planning, integrating and ongoing servicing of cybersecurity, risk management, reliability and security projects and fully managed corporate cybersecurity services.